AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:MDCOThe Medicines Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$84.90
0.00 (0.00 %)
(As of 02/12/2020)
Add
Compare
Today's Range
$84.90
Now: $84.90
$84.90
50-Day Range
$84.90
MA: $84.90
$84.90
52-Week Range
$17.81
Now: $84.90
$84.98
VolumeN/A
Average Volume9.55 million shs
Market Capitalization$6.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.1
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
Read More
The Medicines logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.83 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.14 million
Book Value($0.30) per share

Profitability

Net Income$-123,160,000.00

Miscellaneous

Employees62
Market Cap$6.77 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableOptionable

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of The Medicines?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for The Medicines.

When is The Medicines' next earnings date?

The Medicines is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for The Medicines.

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) issued its quarterly earnings results on Wednesday, October, 30th. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.12. During the same period in the previous year, the business earned ($0.70) earnings per share. View The Medicines' earnings history.

What price target have analysts set for MDCO?

12 brokerages have issued 1 year target prices for The Medicines' shares. Their forecasts range from $49.00 to $145.00. On average, they expect The Medicines' share price to reach $76.75 in the next year. This suggests that the stock has a possible downside of 9.6%. View analysts' price targets for The Medicines.

Has The Medicines been receiving favorable news coverage?

Media coverage about MDCO stock has been trending negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. The Medicines earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about The Medicines.

Who are some of The Medicines' key competitors?

What other stocks do shareholders of The Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Medicines investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), salesforce.com (CRM), Bank of America (BAC), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY) and Celgene (CELG).

Who are The Medicines' key executives?

The Medicines' management team includes the following people:
  • Mr. Mark Timney, CEO & Director (Age 54)
  • Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
  • Dr. Goutham Krishna Gorti, VP & Head of Investor Relations

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $84.90.

How big of a company is The Medicines?

The Medicines has a market capitalization of $6.77 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe.

What is The Medicines' official website?

The official website for The Medicines is www.themedicinescompany.com.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.